6-O-n-Butyryl-ascorbinsaeure | 10583-70-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 6-O-n-Butyryl-ascorbinsaeure
• 英文别名: 5-(2-butyryloxy-1-hydroxy-ethyl)-3,4-dihydroxy-5H-furan-2-one；butyric acid 2-(3,4-dihydroxy-5-oxo-2,5-dihydro-furan-2-yl)-2-hydroxy-ethyl ester；[2-(3,4-dihydroxy-5-oxo-2H-furan-2-yl)-2-hydroxyethyl] butanoate
• CAS: 10583-70-7
• 化学式: C₁₀H₁₄O₇
• 分子量: 246.217
• InChiKey: ACWYFHKSWCNVLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Cyclopentanone derivatives, method of synthesis and uses thereof
  申请人：Neuropharma S.A.

  公开号：EP1939192A1

  公开（公告）日：2008-07-02

  The present invention relates to cyclopentanone derivatives of formula (I), their method of synthesis and uses thereof. Concretely, the compounds disclosed have proved to be inhibitors of glycogen synthase kinase 3β, GSK-3 β, which is known to be involved in different disease and conditions, such as Alzheimer's disease or non-insulin dependent diabetes mellitus. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a GSK-3 mediated disease or condition.

  本发明涉及公式（I）的环戊酮衍生物，其合成方法及用途。具体来说，所披露的化合物已被证明是糖原合成酶激酶3β（GSK-3β）的抑制剂，GSK-3β已知参与不同疾病和病况，如阿尔茨海默病或非胰岛素依赖型糖尿病。本发明还涉及包含这些化合物的药物组合物。此外，本发明旨在将这些化合物用于制造治疗和/或预防GSK-3介导的疾病或病况的药物。
• BRAIN-TARGETING PRODRUG FOR AMPA RECEPTOR SYNERGIST, AND PHARMACEUTICAL APPLICATIONS
  申请人：Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China

  公开号：EP3444240A1

  公开（公告）日：2019-02-20

  Disclosed in the present invention is a compound of Formula (I), a geometric or optical isomer, a pharmaceutically acceptable salt, a solvate or a polymorph thereof. Also disclosed in the present invention is a composition comprising the compound of Formula (I), the geometric or optical isomer, the pharmaceutically acceptable salt, the solvate or the polymorph thereof. Also disclosed in the present invention is a use of the compound of Formula (I), the geometric or optical isomer, the pharmaceutically acceptable salt, the solvate or the polymorph thereof in the treatment of a disease or disorder such as a hypoglutamatergic condition, a neurodegenerative disease or respiratory depression, particularly in the treatment of a disease or disorder associated with AMPA receptor.

  本发明公开了式(I)化合物、几何或光学异构体、药学上可接受的盐、其溶解物或多晶型物。本发明还公开了一种包含式（I）化合物、几何或光学异构体、药学上可接受的盐、其溶液或其多晶型的组合物。本发明还公开了式(I)化合物、几何异构体或光学异构体、药学上可接受的盐、其溶解物或其多晶型在治疗疾病或紊乱中的用途，例如低谷氨酸症、神经退行性疾病或呼吸抑制，特别是在治疗与AMPA受体相关的疾病或紊乱中的用途。
• [EN] CYCLOPENTANONE DERIVATIVES, METHOD OF SYNTHESIS AND USES THEREOF<br/>[FR] DÉRIVÉES DE CYCLOPENTANONE, LEUR MÉTHODE DE SYNTHÈSE ET LEURS UTILISATIONS
  申请人：NEUROPHARMA SA

  公开号：WO2008080988A2

  公开（公告）日：2008-07-10

  [EN] The present invention relates to cyclopentanone derivatives of formula (I), their method of synthesis and uses thereof. Also, the present invention relates to the use of cyclopentanone derivatives of formula (Ia). Concretely, the compounds disclosed have proved to be inhibitors of glycogen synthase kinase 3ß, GSK-3 ß, which is known to be involved in different disease and conditions, such as Alzheimer's disease or non-insulin dependent diabetes mellitus. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a GSK-3 mediated disease or condition.
  [FR] L'invention porte sur des dérivées de cyclopentanone de formule (I), leur méthode de synthèse, et leurs utilisations. L'invention porte également sur l'utilisation des dérivées de cyclopentanone de formule (Ia). Concrètement, les composés de l'invention se sont avérés être des inhibiteurs de la kinase de la synthase du glycogène 3ß, GSK-3 ß, que l'on sait être impliquée dans différente maladie et états, dont la maladie d'Alzheimer ou le diabète sucré non insulinodépendant. L'invention porte également sur l'utilisation de ces composés dans la production de médicaments traitant et/ou prévenant des maladie et états médiées par la GSK-3.